Search results
Showing 901 to 950 of 3030 results for all
Asthma: diagnosis, monitoring and chronic asthma management (BTS, NICE, SIGN) (NG245)
This guideline covers diagnosing, monitoring and managing asthma in adults, young people and children. It aims to improve the accuracy of diagnosis, help people to control their asthma and reduce the risk of asthma attacks. It does not cover managing severe asthma or acute asthma attacks.
This guideline covers the routine postnatal care that women and their babies should receive in the first 8 weeks after the birth. It includes the organisation and delivery of postnatal care, identifying and managing common and serious health problems in women and their babies, how to help parents form strong relationships with their babies, and baby feeding. The recommendations on emotional attachment and baby feeding also cover the antenatal period.
Evidence-based recommendations on everolimus (Afinitor) and sunitinib (Sutent) for treating neuroendocrine tumours in adults.
Evidence-based recommendations on selumetinib (Koselugo) for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 and over.
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development Reference number: GID-HST10062 Expected publication date: 17 March 2027
Bipolar, schizophrenia and other psychoses: 6 physical health checks (IND248)
This indicator covers the percentage of patients with schizophrenia, bipolar affective disorder and other psychoses who, in the preceding 12 months, received all 6 elements of physical health checks for people with severe mental illness. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as NM232
This quality standard covers diagnosing and managing multiple sclerosis (MS) in adults. It includes care, support and review for people with MS. It describes high-quality care in priority areas for improvement.
View quality statements for QS108Show all sections
Evidence-based recommendations on rimegepant (Vydura) for the acute treatment of migraine in adults.
Evidence-based recommendations on cabotegravir (Vocabria) with rilpivirine (Rekambys) for treating HIV-1 in adults. This includes adults with virological suppression (HIV-1 RNA fewer than 50 copies/ml) on a stable antiretroviral regimen, and without any evidence of viral resistance to, and no previous virological failure with, any non-nucleoside reverse transcriptase inhibitors or integrase inhibitors.
Evidence-based recommendations on erlotinib (Tarceva) for treating EGFR-TK-positive non-small-cell lung cancer in adults.
Evidence-based recommendations on durvalumab (Imfinzi) with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancer in adults.
Show all sections
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (HST34)
Evidence-based recommendations on cerliponase alfa (Brineura) for treating neuronal ceroid lipofuscinosis type 2 in children.
NICE technology appraisal and highly specialised technologies guidance: the manual (PMG36)
This guide describes the methods and processes, including expected timescales, that NICE follows when carrying out health technology evaluations. The methods and processes are designed to produce robust guidance for the NHS in an open, transparent and timely way, with appropriate contribution from stakeholders. Organisations invited to contribute to health technology evaluation development should read this manual in conjunction with the NICE health technology evaluation topic selection: the manual. All documents are available on the NICE website
Evidence-based recommendations on certolizumab pegol (Cimzia) for treating severe active rheumatoid arthritis in adults who have had a tumour necrosis factor-alpha inhibitor.
Evidence-based recommendations on atezolizumab (Tecentriq) with nab-paclitaxel for triple-negative, unresectable, PD-L1-positive, locally advanced or metastatic breast cancer in adults who have not had chemotherapy for metastatic disease.
Guide to the technology appraisal and highly specialised technologies appeal process (PMG41)
This guide outlines the appeal process for the technology appraisal and highly specialised technologies guidance. It sets out the process that NICE follows for appeals and provides guidance for those who wish to make an appeal or who are considering doing so
Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia (TA733)
Evidence-based recommendations on inclisiran (Leqvio) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.
Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C in adults.
This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used
to know in advance what will happen to any individual person. c NICE 2019. All rights reserved. Subject to Notice of rights. Last...
to know in advance what will happen to any individual person. c NICE 2019. All rights reserved. Subject to Notice of rights. Last...
Abortion care. Patient decision aid on choosing between medical or surgical abortion before 14 weeks
things that are important to you. Talk to your healthcare professional about all your concerns so that you can make an informed choice....
Pulmonary artery pressure technologies for remote monitoring of chronic heart failure (HTG769)
Evidence-based recommendation on the routine use of pulmonary artery pressure technologies for remote monitoring of chronic heart failure.
Avelumab for untreated metastatic Merkel cell carcinoma (TA691)
Evidence-based recommendations on avelumab (Bavencio) for untreated metastatic Merkel cell carcinoma in adults.
Show all sections
Evidence-based recommendations on rituximab for treating relapsed or refractory stage 3 or 4 follicular non-Hodgkin's lymphoma in adults.
Apixaban for preventing venous thromboembolism after hip or knee replacement surgery (TA245)
Evidence-based recommendations on apixaban (Eliquis) for preventing venous thromboembolism after hip or knee replacement in adults.
View recommendations for TA245Show all sections
Evidence-based recommendations on cetuximab (Erbitux), bevacizumab (Avastin) and panitumumab (Vectibix) for treating metastatic colorectal cancer in adults.
Evidence-based recommendations on ripretinib (Qinlock) for treating advanced gastrointestinal stromal tumours after 3 or more kinase inhibitors in adults.
Show all sections
Interim methods guide for developing service guidance 2014 (PMG8)
This manual provides information additional to that in Developing NICE guidelines: the manual to guide developers on how to approach developing service guidance, and also to inform stakeholders about the steps that NICE will take in developing this guidance
Summary of the evidence on avanafil for treating erectile dysfunction to inform local NHS planning and decision-making
High dose rate brachytherapy for carcinoma of the cervix (HTG104)
Evidence-based recommendations on high dose rate brachytherapy for carinoma of the cervix. This involves giving radiation at a high dose rate to the cervix (reducing the timeframe compared with low or medium dose rates) to treat the cancer.
View recommendations for HTG104Show all sections
Sections for HTG104
This guideline covers diagnosing and managing renal cell carcinoma in people aged 18 and over. It aims to improve care by helping healthcare professionals offer people the right treatments and support, taking into account the person’s individual preferences.
Show all sections
Sections for NG256
- Overview
- Information and support
- Diagnosis
- Managing oncocytomas and Bosniak 2F cysts
- Managing localised and locally advanced renal cell carcinoma
- Managing advanced renal cell carcinoma
- Managing renal cell carcinoma in people with a heritable renal cell carcinoma predisposition syndrome
- Terms used in this guideline
Interim process and methods for developing rapid guidelines on COVID-19 (PMG35)
This guide sets out the process and methods used to develop rapid guidelines on COVID-19
NICE health technology evaluation topic selection: the manual (PMG37)
This manual sets out the process for deciding how topics are identified, selected and routed for NICE guidance developed by the Centre for Health Technology Evaluation (CHTE). This includes diagnostics, highly specialised technologies, interventional procedures, medical technologies and technology appraisal guidance
Summary of the evidence on cangrelor for coronary revascularisation to inform local NHS planning and decision-making
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure in adults.
Filgotinib for treating moderately to severely active ulcerative colitis (TA792)
Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.
Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma (TA121)
Evidence-based recommendations on carmustine implants (Gliadel) and temozolomide for treating newly diagnosed high-grade glioma in adults.
View recommendations for TA121Show all sections
Evidence-based recommendations on enzalutamide (Xtandi) for treating metastatic hormone-relapsed prostate cancer in adults who have had treatment with docetaxel-containing chemotherapy.
Endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence (HTG262)
Evidence-based recommendations on endoscopic radiofrequency therapy of the anal sphincter for faecal incontinence. This involves applying radiofrequency energy to the anal wall, with the aim of inducing muscle changes to improve muscle tone and help control bowel movement.
View recommendations for HTG262Show all sections
Sections for HTG262
time of the invitation to participate which will include taking account of all relevant considerations arising out of the interim access...
Summary of the evidence on oral erythromycin for gastroparesis (delayed stomach emptying) in adults to inform local NHS planning and decision-making
Insertion of a magnetic bead band for faecal incontinence (HTG336)
Evidence-based recommendations on insertion of a magnetic-bead band for faecal incontinence. This involves placing a ring of magnetic beads into a tunnel made around the anus to prevent incontinence.
View recommendations for HTG336Show all sections
Sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse (HTG435)
Evidence-based recommendations on sacrocolpopexy with hysterectomy using mesh to repair uterine prolapse. This involves attaching mesh from the top of the vagina to the base of the spine to support the pelvic organs after the womb has been removed.
Uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse (HTG445)
Evidence-based recommendations on uterine suspension using mesh (including sacrohysteropexy) to repair uterine prolapse in women. This involves attaching mesh from the uterus or cervix either to the bone at the base of the spine or to a ligament in the pelvis to hold the uterus in place.
Summary of the evidence on rifaximin for treating pouchitis to inform local NHS planning and decision-making
Methods for the development of NICE public health guidance (third edition) (PMG4)
This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance
Evidence-based recommendations on gefitinib (Iressa) for untreated locally advanced or metastatic non-small-cell lung cancer in adults.
Selinexor with bortezomib and dexamethasone for previously treated multiple myeloma (TA974)
Evidence-based recommendations on selinexor (Nexpovio) with bortezomib and dexamethasone for previously treated multiple myeloma in adults.